ASCO Conference Coverage
Featured News
(BioPharma Dive) June 5, 2019 - An AstraZeneca cancer drug works best in people with an uncommon mutation. For a recent study evaluating whether the drug offered benefits to pancreatic cancer who have the mutation, researchers screened more than 3,300 patients. Only 247 of them tested positive, and even fewer participated in the...
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA breast cancer genes responded to olaparib. And even though men...
(MedPage Today) June 3, 2019 - A year-long overall survival (OS) improvement with olaratumab (Lartruvo) in an early-phase soft-tissue sarcoma trial disappeared when the drug was tested in a larger phase III trial. Among more than 500 doxorubicin-treated patients in ANNOUNCE, those randomized to olaratumab had a median OS of 20.4...
(STAT Plus) June 3, 2019 - Precision medicine in lung cancer is making a big impact at this year’s ASCO meeting. Rare mutations in lung tumors discovered through genetic screening are leading to the development of highly targeted drugs. And these drugs are shrinking tumors in patients not helped by current treatments. Two case...
(The Guardian/Press Association [UK]) June 3, 2019 - Immunotherapy could help patients with head and neck cancer live longer, new research suggests. The drug pembrolizumab, used in combination with platinum chemotherapy, was found to extend survival among those whose disease had returned or spread, according to a study presented at...
(BioPharma Dive) June 3, 2019 - Decades of research have failed to uncover a therapeutic answer to one of the most well-known genetic drivers of cancer. Yet Amgen thinks it's broken through with an early-stage drug that, in initial results presented Monday at the American Society of Clinical Oncology's annual meeting, spurred tumors to...
(Yale Cancer Center) June 3, 2019 - There are no approved treatment options for patients with advanced bladder cancer after standard chemotherapy and immune treatments, but the results of a phase II clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers demonstrates an effective treatment for this deadly disease....
(MedPage Today) June 3, 2019 - Minimally-invasive laparoscopic surgery successfully eliminated colorectal metastases in the liver, providing the same long-term survival and disease-free recurrence risk as open surgery, researchers reported here. After 5 years, 57% of the 147 patients undergoing open surgery in the intention-to-treat...
(CNN) June 2, 2019 - When most people hear about BRCA genes, they immediately think about how inherited mutations in those genes -- BRCA1 and BRCA2 -- have been linked with higher risk of breast and ovarian cancer. Yet researchers have long known that several cancers other than breast and ovarian are associated with harmful mutations...
(Dana-Farber) June 2, 2019 - After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic...
(Washington Post) June 2, 2019 - Proponents of the embattled Affordable Care Act got additional ammunition Sunday: New research links the law to a reduction in racial disparities in the care of cancer patients and to earlier diagnoses and treatment of ovarian cancer, one of the most dangerous malignancies. The findings, coming as...
(NBC News) June 1, 2019 - Women with an aggressive and deadly form of breast cancer may live longer if they're treated with a drug that targets breast cancer cells specifically, according to the results of a new clinical trial. The drug, called ribociclib, was given alongside another type of cancer treatment: hormone therapy. In the...
(Reuters) June 1, 2019 - Nearly a quarter of patients who received Merck & Co’s immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting on Saturday. That represents a huge gain over the historical five-year survival rate of...
(Cancer Research UK) June 1, 2019 - An immunotherapy drug could prove just as effective as chemotherapy in prolonging the lives of patients with advanced cancers of the stomach or food pipe. For some, the immune-boosting treatment offered improved survival compared to standard treatment. The immunotherapy, called pembrolizumab...
(Pharmaphorum.com [UK]) June 1, 2019 - Johnson & Johnson is hoping to expand the use of its prostate cancer drug Erleada (apalutamide) in patients with metastatic castration-sensitive prostate cancer (mCSPC) – and new data presented at ASCO sheds light on the dossier under review at the FDA for this early stage disease. Developed by...
(Chicago Tribune/Associated Press) May 31, 2019 - California company says its experimental blood test was able to detect many types of cancer at an early stage and gave very few false alarms in a study that included people with and without the disease. Grail gave results in a news release on Friday and will report them Saturday at the...
(Iovance) May 31, 2019 - Complete Response rate of 11 percent observed in the LN-145 study in cervical cancer. Median duration of response has not been reached at 7.4 month median follow-up in the ongoing study of LN-145 in advanced cervical cancer. Median duration of response has not been reached at 8.8 month median follow-up in the...
(Merck) May 31, 2019 - Merck, known as MSD outside the United States and Canada, today announced the presentation of the final analysis of the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy, for the first-line treatment of patients with recurrent...
(Boston Globe) May 30, 2019 - Eleven years after it was founded, the Cambridge, Mass.-based biopharmaceutical startup Epizyme on Thursday sought early approval of an experimental medicine to treat an ultra-rare form of cancerous tumors. If successful, the drug would be the company’s first to reach the market. Based on encouraging...
(BioPharma Dive) May 22, 2019 - The failure of Incyte's epacadostat last year cooled enthusiasm for cancer immunotherapies designed to build upon the strong foundation laid by the PD-(L)1 inhibitor class, now led by Merck & Co.'s Keytruda. Yet early- and mid-stage work continues on agents that either block the defenses against immune...
(STAT) May 15, 2019 - Scientists have long known that a mutant form of the cell-signaling protein called KRAS causes cancer, but discovering drugs capable of blocking KRAS has proven difficult. The protein is spherical and nearly featureless — its structure has been compared to a tennis ball — leaving potential drugs with few, if...
(2019 ASCO) May 15, 2019 - In a phase I/IB study of 29 patients, age 4.9 months to 20 years, with rare central nervous system tumors, neuroblastoma, or other solid tumors, responses to entrectinib, a novel targeted treatment, were seen in 12 of the 28 evaluable patients. The 12 pediatric patients who experienced a response to therapy had...
(NBCNews.com) May 15, 2019 - Eating a low-fat, plant-based diet could help significantly lower a woman's risk of dying from breast cancer, and the key appears to be changing eating habits before tumors have a chance to develop, according to a study released Wednesday. The new findings are from a long-term analysis of the federally...
(Morningstar) May 13, 2019 - Data include new analyses on Vitrakvi® (larotrectinib), with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion. First detailed presentation of quality of life data from the Phase III ARAMIS trial of the investigational androgen receptor antagonist darolutamide in patients...
(Genentech) May 9, 2019 - New pivotal data on fixed-duration combination of Venclexta plus Gazyva in previously untreated chronic lymphocytic leukemia. New data for entrectinib in pediatric patients with recurrent or refractory solid tumors harboring NTRK, ROS1 or ALK gene fusions. Genentech, a member of the Roche Group, today...
(ASCO) Apr 17, 2019 - Cancer experts from around the world will gather to share the latest clinical cancer research impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in targeted therapies for pancreatic, prostate, and pediatric cancers, as well as new approaches to overcoming...
View all
More News
(ESMO) June 25, 2019 - Results of the NEOSTAR and LCMC3 studies that tested neoadjuvant immune checkpoint blockade in resectable non-small cell lung cancer (NSCLC) were presented at 2019 ASCO Annual Meeting.
(Medscape Medical News) June 13, 2019 - The federal government's Oncology Care Model (OCM) is based on the idea that you can motivate clinicians with cash rewards to improve care and reduce costs.
(Xconomy San Diego) June 12, 2019 - Oncternal Therapeutics has joined the growing ranks of San Diego biotechs to go public, but it didn’t go through an IPO to get there.
(Medscape Medical News) June 10, 2019 - Ashley Glode, PharmD, a pharmacist in the gastrointestinal clinic at the University of Colorado Cancer Center, Anshutz, says marijuana is not a taboo topic in her state, where medical use was approved in 2000 and recreational use in 2012.
(Medscape Medical News) June 7, 2019 - Since the inception of the Open Payments program, fewer American medical oncologists appear to be engaging with industry, new findings show.
(Physician’s Weekly) June 5, 2019 - One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies.
(UNC LCCC) June 2, 2019 - Preliminary results from a University of North Carolina Lineberger Comprehensive Cancer Center study found that just 15 percent of a group of men in North Carolina with early-stage prostate cancer who choose active surveillance instead of treatment followed the recommended monitoring guidelines.
(Washington Post/Bloomberg) June 5, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO), which wrapped up Tuesday, is one of the drug industry’s most prominent platforms for showcasing promising cancer research and treatments. This year was no exception.
(The Center For Biosimilars) June 6, 2019 - During this week’s 2019 American Society of Clinical Oncology Annual Meeting, researchers reported on the cardiac safety of Amgen’s biosimilar trastuzumab, ABP 980 (approved in the European Union under the name Kanjinti), versus the reference trastuzumab, Herceptin.
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA breast cancer genes responded to olaparib. And even though men...
(MedPage Today) June 3, 2019 - A year-long overall survival (OS) improvement with olaratumab (Lartruvo) in an early-phase soft-tissue sarcoma trial disappeared when the drug was tested in a larger phase III trial. Among more than 500 doxorubicin-treated patients in ANNOUNCE, those randomized to olaratumab had a median OS of 20.4...
(MedPage Today) June 4, 2019 - Early randomized trial of capivasertib shows promise in ER-positive disease.
(BioSpace) June 4, 2019 - Results, presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated clinically meaningful response in patients with urothelial carcinoma whose treatment previously failed, a population with high unmet medical need.
(Yahoo! Finance) June 4, 2019 - TG Therapeutics, Inc. today presented positive interim data from the ongoing single-arm marginal zone lymphoma (MZL) cohort of its Phase 2b UNITY-NHL trial currently evaluating umbralisib as a single agent in patients with relapsed/refractory MZL.
Featured Videos
There are no featured ASCO Conference Coverage videos.

OBR Tweets

Jul 09
H. Jack West, MD: The benefit of low dose chest CT screening for lung cancer remains somewhat controversial, but th… https://t.co/8wOgsSCY7q

Jul 08
Howard S. Hochster, MD: While a "complete response" is great for our patients, the Complete Response Letter was les… https://t.co/yQGkfvpMCF

Jul 02
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ve0XD0cWDY

Jul 01
A report on several promising studies at #ASCO20 focused on personalized therapies for patients with unmet needs. I… https://t.co/lc4BoQ3Evl

Jul 01
At #ASCO’s virtual meeting, studies featured potentially practice-changing data. Among the studies were the BOSTON… https://t.co/6pXpxFomwu

Jun 22
Howard S. Hochster, MD: Another, but far more problematic approval for Pembro. Which tumors actually have high TMB… https://t.co/pBSquns9mN

Jun 19
Dean Gesme, MD: The positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E… https://t.co/GXnYhO8jov

Jun 17
Thomas Marsland, MD: I actually enjoyed the experience. I certainly missed mingling with friends and colleagues. Al… https://t.co/gVtYjkzPzy

Jun 16
Derek Raghavan, MD, on @LevineCancer provides a general overview of prostate cancer therapies #ASCO20 https://t.co/niwz0yPHjB

Jun 16
H. Jack West, MD: We await phase 3 data, but many will welcome a new option with an approximately 35% response rate… https://t.co/Ld5N8KrWye